References and Notes
<A NAME="RG15107ST-1">1</A>
Kolb HC.
Finn MG.
Sharpless KB.
Angew. Chem. Int. Ed.
2001,
40:
2004
<A NAME="RG15107ST-2">2</A>
Sekar G.
Singh VK.
J. Org. Chem.
1999,
64:
287
<A NAME="RG15107ST-3A">3a</A>
Ollevier T.
Lavie-Compin G.
Tetrahedron Lett.
2004,
45:
49
<A NAME="RG15107ST-3B">3b</A>
Chakraborti AK.
Kondaskar A.
Tetrahedron Lett.
2003,
44:
8315
<A NAME="RG15107ST-3C">3c</A>
Fringuelli F.
Pizzo F.
Tortoioli S.
Vaccaro L.
J. Org. Chem.
2004,
69:
7745
<A NAME="RG15107ST-3D">3d</A>
Sekar G.
Singh VK.
J. Org. Chem.
1999,
64:
287
<A NAME="RG15107ST-4">4</A>
Fringuelli F.
Piermatti O.
Pizzo F.
Vaccaio L.
J. Org. Chem.
1999,
64:
6094
<A NAME="RG15107ST-5A">5a</A>
Mojtahedi MM.
Saidi MR.
Bolourtchian M.
J. Chem. Res., Synop.
1999,
128
<A NAME="RG15107ST-5B">5b</A>
Eshghi H.
Rahimizadeh M.
Shoryabi A.
Synth. Commun.
2005,
35:
791
<A NAME="RG15107ST-5C">5c</A>
Rodríguez-Escrich S.
Popa D.
Jimeno C.
Vidal-Ferran A.
Pericàs MA.
Org. Lett.
2005,
7:
3829
<A NAME="RG15107ST-6">6</A>
Cravotto G.
Cintas P.
Chem. Eur. J.
2007,
13:
1902
<A NAME="RG15107ST-7">7</A> The use of 1-(3-chlorophenyl)piperazine refers to the work of:
Narayan N.
Muldoon J.
Finn MG.
Fikin VV.
Kolb HC.
Sharpless KB.
Angew. Chem. Int. Ed.
2005,
44:
3275
<A NAME="RG15107ST-8">8</A>
Cravotto G.
Omiccioli G.
Stevanato L.
Ultrason. Sonochem.
2005,
12:
213
<A NAME="RG15107ST-9">9</A>
Cravotto G.
Boffa L.
Bia M.
Bonrath W.
Curini M.
Heropoulos GA.
Synlett
2006,
2605
<A NAME="RG15107ST-10">10</A>
Cravotto G,
Buffa C, and
Omiccioli G. inventors; TO patent application A000766.
<A NAME="RG15107ST-11">11</A> HSAB theory:
Huyskens P.
Sobczyk L.
Majerz I.
J. Mol. Struct.
2002,
615:
61
<A NAME="RG15107ST-12">12</A>
Azizi N.
Saidi MR.
Org. Lett.
2005,
7:
3649
<A NAME="RG15107ST-13A">13a</A>
Newhall WF.
J. Org. Chem.
1964,
29:
185
<A NAME="RG15107ST-13B">13b</A>
Steiner D.
Ivison L.
Goralski CT.
Appell RB.
Gojkovic JR.
Singaram B.
Tetrahedron: Asymmetry
2002,
13:
2359
<A NAME="RG15107ST-13C">13c</A>
Davis CE.
Bailey JL.
Lockner JW.
Coates RM.
J. Org. Chem.
2003,
68:
75
<A NAME="RG15107ST-14">14</A>
General Procedure
In a 50 mL two-necked round-bottomed flask (equipped with an optical-fiber thermometer
for reactions under MW or combined US/MW) the epoxide (2.5 mmol), the amine (or NaN3, 2.5 mmol), and H2O (15 mL) were mixed and subjected to procedures 1-4.
<A NAME="RG15107ST-15">15</A>
2-[4-(3-Chlorophenyl)piperazin-1-yl]-2-phenylethanol (1Aα): pale yellow oil; R
f
= 0.56 (CHCl3-MeOH, 19:1). IR (film): 3584, 1595, 1452, 1238, 1028, 954, 765 cm-1. 1H NMR (300 MHz, CDCl3): δ = 7.37-7.22 (m, 5 H, H-2′, -3′, -4′, -5′, -6′), 7.14 (t, J = 8.1 Hz, 1 H, H-5′′′), 6.83-6.72 (m, 3 H, H-2′′′, -4′′′, -6′′′), 4.03 (m, 1 H, H-2),
3.74 (m, 2 H, H-2, -3), 3.20 (m, 4 H, H-3′′a,b, H-5′′a,b), 2.74-2.54 (m, 4 H, H-2′′a,b,
H-6′′a,b). MS (CI, isobutane): m/z = 317 [MH]+.
<A NAME="RG15107ST-16">16</A>
2-[4-(3-Chlorophenyl)piperazin-1-yl]-1-phenylethanol (1Aβ): pale yellow oil; R
f
= 0.43 (CHCl3-MeOH, 19:1). IR (film): 3400, 1595, 1566, 1481, 1244, 1057, 947, 777 cm-1. 1H NMR (300 MHz, CDCl3): δ = 7.46-7.38 (m, 5 H, H-2′, -3′, -4′, -5′, -6′), 7.22 (t, J = 8.1 Hz, 1 H, H-5′′′), 6.94-6.83 (m, 2 H, H-2′′′, -4′′′, -6′′′), 4.86 (m, 1 H, H-1),
3.31 (m, 4 H, H-3′′a,b, H-5′′a,b), 2.95-2.92 (m, 2 H, H-2′′a,b), 2.70-2.56 (m, 4 H,
H-2, -3, H-6′′a,b). MS (CI, isobutane): m/z = 317 [MH]+.
<A NAME="RG15107ST-17">17</A>
2-{3-[4-(3-Chlorophenyl)piperazin-1-yl]-2-hydroxypropyl} isoindoline-1,3-dione (2Aβ): pale yellow oil; R
f
= 0.39 (CHCl3-MeOH, 19:1). IR (film): 3327, 1626, 1576, 1437, 1244, 893 cm-1. 1H NMR (300 MHz, CDCl3): δ = 7.87-7.81 (m, 4 H, H-3, -4, -5, -6,), 7.17 (m, 1 H, H-5′′′), 6.80-6.65 (m,
3 H, H-2′′′, -4′′′, -6′′′), 4.21 (m, 1 H, H-2′), 3.50 (m, 2 H, H-1′a,b), 2.57 (m,
2 H, H-3′a,b), 2.90-2.40 (m, 8 H, H-2′′a,b, H-3′′a,b, H-5′′a,b, H-6′′a,b). MS (CI,
isobutane): m/z = 400 [MH]+.
<A NAME="RG15107ST-18">18</A>
1-[4-(3-Chlorophenyl)piperazin-1-yl]octan-2-ol (3Aβ): pale yellow oil; R
f
= 0.40 (hexane-EtOAc, 7:3). IR (film): 3460, 1595, 1487, 1234, 1153, 987, 837, 769
cm-1. 1H NMR (300 MHz, CDCl3): δ = 7.10 (t, J = 8.1 Hz, 1 H, H-2′′), 6.85-6.50 (m, 3 H, H-4′′, -5′′, -6′′), 3.70 (m, 1 H, H-2),
3.10 (m, 4 H, H-3′a,b, H-5′a,b), 2.75 (m, 2 H, H-2′a,b), 2.50 (m, 2 H, H-6′a,b), 2.30
(m, 2 H, H-1a,b), 1.50-1.00 (m, 10 H, H-3a,b, H-4a,b, H-5a,b, H-6a,b, H-7a,b), 0.95
(br s, 3 H, CH3). MS (CI, isobutane): m/z = 325 [MH]+.
<A NAME="RG15107ST-19">19</A>
trans-2-[4-(3-Chlorophenyl)piperazin-1-yl]cyclohexanol (4A): pale yellow oil; R
f
= 0.13 (PE-EtOAc, 8:2). IR (film): 3462, 1597, 1495, 1263, 1105, 1014, 954, 771,
681 cm-1. 1H NMR (300 MHz, CDCl3): δ = 7.02-6.77 (m, 4 H, H-2′′, -4′′, -5′′, -6′′), 4.16 (m, 1 H, H-1), 3.43 (m, 1
H, H-2), 3.23-3.19 (m, 4 H, H-3′a,b, H-5′a,b), 2.88 (m, 2 H, H-2′a,b), 2.58 (m, 2
H, H-5′a,b), 2.40-1.15 (m, 8 H, H-3,a,b, H-4a,b, H-5a,b, H-6a,b). MS (CI, isobutane):
m/z = 295 [MH]+.
<A NAME="RG15107ST-20">20</A>
(1R,2R)-2-[4-(3-Chlorophenyl)piperazin-1-yl]-1-methyl-4-(prop-1-en-2-yl)cyclohexanol (5Aβ): pale yellow oil; R
f
= 0.62 (hexane-EtOAc, 7:3). IR (film): 3462, 2361, 1595, 1450, 1238, 1126, 987, 767
cm-1. 1H NMR (300 MHz, CDCl3): δ = 7.17 (t, J = 8.1 Hz, 1 H, H-2′′′), 6.87 (m, 3 H, H-4, -5, -6), 4.96 (m, 1 H, H-9a), 4.87 (m,
1 H, H-9b), 3.47 (m, 1 H, H-2), 3.22 (m, 4 H, H-3′′a,b, H-5′′a,b), 2.90 (m, 2 H, H-2′′a,b),
2.68 (m, 2 H, H6′′a,b), 2.5 (br s, 1 H, OH). MS (CI, isobutane): m/z = 349 [MH]+.
<A NAME="RG15107ST-21">21</A>
(1R,2R,4R)-2-Azido-1-methyl-4-(prop-1-en-2-yl)cyclo-hexanol (5Bβ): colorless oil; R
f
= 0.24 (CHCl3-MeOH, 19:1). IR (film): 3450, 2094, 1645, 1454, 1261, 1032, 891 cm-1. 1H NMR (300 MHz, CDCl3): δ = 4.8 (m, 2 H, H-9a,b), 3.55 (br s, 1 H, H-2), 2.20 (m, 1 H, H-4), 2.00 (m, 1
H, H-3a), 1.85 (m, 1 H, H-3b), 1.73 (m, 3 H, H-10, CH3), 1.45 (br s, 1 H, OH), 1.40 (m, 3 H, H-7, CH3). MS (CI, isobutane): m/z = 196 [MH]+.